Trials / Completed
CompletedNCT04657003
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 938 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study of tirzepatide in participants with type 2 diabetes who have obesity or are overweight. The main purpose is to learn more about how tirzepatide affects body weight. The study will last 79 weeks (22 visits).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tirzepatide | Administered SC |
| OTHER | Placebo | Administered SC |
Timeline
- Start date
- 2021-03-29
- Primary completion
- 2023-03-16
- Completion
- 2023-04-10
- First posted
- 2020-12-07
- Last updated
- 2024-04-08
- Results posted
- 2024-04-08
Locations
75 sites across 8 countries: United States, Argentina, Brazil, India, Japan, Puerto Rico, Russia, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04657003. Inclusion in this directory is not an endorsement.